Vascular Remodeling in
Health and Disease Luis G. Melo, Massimiliano Gnecchi, Christopher A. Ward, and Victor J. Dzau he term vascular remodeling is commonly used to defi ne the structural changes in blood vessel geometry that occur in response to long-term physiologic alterations in blood fl ow or in response to vessel wall injury brought about by trauma or underlying cardiovascular diseases. [1] [2] [3] [4] The process of remodeling, which begins as an adaptive response to long-term hemodynamic alterations such as elevated shear stress or increased intravascular pressure, may eventually become maladaptive, leading to impaired vascular function. The vascular endothelium, owing to its location lining the lumen of blood vessels, plays a pivotal role in regulation of all aspects of vascular function and homeostasis. 5 Thus, not surprisingly, endothelial dysfunction has been recognized as the harbinger of all major cardiovascular diseases such as hypertension, atherosclerosis, and diabetes. [6] [7] [8] The endothelium elaborates a variety of substances that infl uence vascular tone and protect the vessel wall against infl ammatory cell adhesion, thrombus formation, and vascular cell proliferation. [8] [9] [10] Among the primary biologic mediators emanating from the endothelium is nitric oxide (NO) and the arachidonic acid metabolite prostacyclin [prostaglandin I 2 (PGI 2 )], which exert powerful vasodilatory, antiadhesive, and antiproliferative effects in the vessel wall. In addition, the endothelium produces a variety of vasoconstrictor and proadhesion molecules such as endothelin-1, angiotensin II (Ang II), and thromboxanes, which counteract the effects of NO and PGI 2 . In normal conditions these opposing modulators from the endothelium are in equilibrium, and vessel wall homeostasis is maintained. 5 However, in the presence of sustained pathophysiologic stimuli such as hypertension, hyperlipidemia, and hyperglycemia, the availability of protective moieties such as NO and PGI 2 are reduced, leading to increased vascular tone and enhanced infl ammatory cell and platelet adhesion and proliferation of the media smooth muscle, which may increase the occurrence of thrombosis and vascular occlusion. [7] [8] [9] [10] Vascular remodeling is a complex and highly regulated process involving the activation of multiple signaling cas-cades and downstream transcription factors, which function coordinately to induce the expression of a plethora of genes involved in vascular cell growth, proliferation, apoptosis, migration, and adhesion, and extracellular matrix synthesis and breakdown. [10] [11] [12] [13] [14] [15] All components of the vascular wall appear to be involved in the remodeling process, [16] [17] [18] and recent evidence suggests that circulating smooth muscle and endothelial progenitor cells originating from the bone marrow may actively participate in vessel remodeling in atherosclerosis and in restenosis associated with revascularization procedures such as angioplasty and bypass vein grafting. [19] [20] [21] [22] [23] [24] [25] It is now apparent that oxidative stress is a primary cause of endothelial dysfunction, and reactive oxygen species produced by the vascular cells and infi ltrating infl ammatory cells play a central role in activating the molecular signals leading to vessel remodeling.
Therapeutic strategies to prevent the negative effects of vessel remodeling have focused on the use of drugs aimed at normalizing blood pressure and circulating cholesterol and glucose levels. Drugs targeting the activity of the reninangiotensin system [angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers], hepatic hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins), and activators of peroxisome proliferator-activated receptors (fi brates, glitazones) have been shown to improve endothelial function and to inhibit vascular remodeling in hypertensive and hypercholesterolemic patients. [26] [27] [28] [29] Surgical strategies using drug-eluting stents releasing cytostatic drugs such as rapamycin have been reported to reduce the rate of restenosis in patients undergoing percutaneous angioplasty and bypass grafting, [30] [31] [32] [33] and novel genetic and cell therapy modalities are emerging on the horizon for treatment of vasculoproliferative disease and repair of damaged blood vessels. 34, 35 This chapter reviews the basic mechanisms involved in vascular remodeling in physiologic and pathophysiologic conditions, and the current and emerging therapies for prevention of remodeling in vascular disease.
T Vascular Remodeling in Physiologic and Pathologic States
The type and magnitude of structural change that a blood vessel endures during the process of vascular remodeling is determined not only by the type of stimuli impacting those changes but also by the location of the vessels, such that, for example, the type of remodeling in small resistance vessels from hypertensive patients is different from the remodeling taking place in large conduit arteries. [1] [2] [3] Furthermore, although changes in hemodynamic forces (pressure, fl ow) are the primary determinants of remodeling in physiologic and pathologic conditions, 1-3,36-38 a variety of pathophysiologic stimuli such as infl ammation, 1, 13, 14 oxidative stress, 1, 8, 40 and apoptosis 2, 12 contribute to vascular remodeling in vascular disease, leading to endothelial dysfunction and an imbalance in the production of vasoregulatory and growth-promoting and growth-inhibiting factors, resulting in abnormal vascular function and structure. The most common cardiovascular disorders that are characterized by abnormal vascular function and structure are hypertension, atherosclerosis, postangioplasty restenosis, and graft atherosclerosis. 1, 2, 8, 12, 13, 39, [41] [42] [43] Although the pathophysiologic processes of these disorders are complex and involve the participation of multiple cell types, biologically active molecules, extracellular matrix modulation, and so forth, a predominant feature of all these diseases is abnormal smooth muscle growth. [41] [42] [43] 
Vascular Remodeling in Response to Alterations in Blood Flow
The relationship between blood fl ow and vessel structure was fi rst demonstrated by Langille and O'Donnell. 38 In their seminal study, these authors showed that a reduction in fl ow for up to 1 month through the common carotid of young rabbits led to a decrease in vessel diameter of approximately 70%. Conversely, an increase in basal blood fl ow was associated with an increase in vessel diameter. This chronic effect was due to a structural rather than a functional modifi cation of the arterial wall. The alterations in vessel diameter brought about by changes in blood fl ow were associated with alterations in elastin accumulation and medial smooth muscle proliferation, which are deposited in the circumferential direction, where fl ow reduction led to a marked decrease in elastin and DNA accumulation in the vessel wall. 38 The vascular remodeling response to changes in fl ow appears to be exclusively mediated by the endothelium, because the fl ow-induced changes in vessel diameter are fully abolished by removal of the endothelium. 39, 44 The endothelial mechanism mediating these structural effects remains undefi ned. A plausible mechanism is that the endothelium senses alterations in shear stress and induces changes in vessel structure by producing mediators that regulate cell growth, extracellular matrix production, and proteolysis. Although many mediators may be involved in vascular remodeling, experimental evidence suggests that fl ow stimulates the release of NO, platelet-derived growth factor (PDGF), and transforming growth factor-β 1 (TGF-β 1 ) (reviewed elsewhere 10, 45 ). Nitric oxide, in particular, plays an obligatory role in fl ow-induced vascular remodeling. For example, Tronc and colleagues 46 showed that the increase in vessel diameter associated with increased blood fl ow in a rabbit arteriovenous fi stula model was abolished by chronic treatment with the nitric oxide synthase inhibitor NG-nitro-L-arginine methylester. Similarly, using a rat model of combined unilateral external and internal carotid ligation, Miyashito and colleagues 47 reported fl ow-induced adaptive remodeling of the contralateral artery with increased fl ow. Conversely, reduction in blood fl ow in the common carotid of endothelial nitric oxide synthase (eNOS) knockout mice failed to elicit the expected decrease in vessel diameter, leading instead to a paradoxical increase in wall thickness associated with media hyperplasia, whereas the wild-type mice responded normally with a reduction in internal diameter in response to the decrease in fl ow triggered by ligation of the ipsilateral external carotid artery. 44 These authors further documented the time course of reduced fl ow-induced remodeling of the common carotid in mice and reported that the decrease in vessel diameter, although fully reversible 3 days after ligation by perfusion with vasodilators, the reduction in diameter was permanent after 7 days of fl ow reduction in association with impaired NO production. 48 There are multiple examples where physiologic alterations in basal blood fl ow are accompanied by vessel re modeling. For example, epicardial coronary arteries were reported to be enlarged in physically active rats compared with sedentary litter mates, 49-52 and short-term exercise training of dogs produces a signifi cant increase in epicardial coronary artery diameter of their epicardial coronary arteries, 53 presumably to accommodate the required need for increased myocardial blood fl ow. Similarly, men with physically active occupations have larger than expected coronary arteries. 54, 55 A commonly cited example is the case report based on the autopsy of the marathon runner Clarence De Mar, which reported epicardial vessels that were "two or three times the normal size." 56 Mann and colleagues 57 found that vigorously active Masai tribesmen dying of noncardiovascular causes and with no clinical evidence of coronary disease had as much coronary atherosclerosis at autopsy as American men but had patent arterial lumina because of the large size of their epicardial vessels. Rose and associates 54 at autopsy studied the hearts of a group of men and women with and without infarction and found an association between increasing physical activity of occupation and increasing coronary artery diameter. Several cross-sectional 58, 59 and exercise-training 60, 61 studies have demonstrated that in trained men and women, there is signifi cantly greater hyperemic blood fl ow in the calf and forearm, even after correction for differences in muscle mass. These results are consistent with a greater capacity for dilatation in the vasculature of trained skeletal muscle unrelated to muscle hypertrophy. The increased blood fl ow appears to be due to adaptation of the vascular structure, possibly an increase in the caliber or number of resistance arterioles. The benefi cial effects of exercise training at least in part may be due to fl ow-induced changes in vascular structure and reactivity, probably associated with enhanced basal NO production. 60, 61 Others have shown that endothelial dependent vasomotor responses are modulated by alterations in blood fl ow. For example, Miller and colleagues 62 showed that an increase in femoral blood fl ow for 6 weeks in dogs via arteriovenous fi stula led to enhanced endothelial function in the vessel exposed to increased fl ow. Conversely, a chronic decrease in blood fl ow associated with low cardiac output leads to reduced endothelial function in animal models of heart failure. 63, 64 Flow-related changes in vascular remodeling have also been seen in clinical situations. Perhaps the most striking example is seen in patients with arteriovenous fi stulas. In these patients, coronary fl ow is dramatically increased in association with a marked increase in the diameter and tortuosity of the vessel involved in the fi stula. 65 Evidence of fl ow-induced remodeling is also often seen in patients with coronary artery disease. Glagov and associates 66 found that many atherosclerotic vessels with signifi cant atheroma maintained normal lumen diameter via enlargement of the vessel wall. They proposed that as the lumen is narrowed by accumulating atheroma, the resultant increase in shear stress may induce remodeling of the vessel wall akin to fl owinduced remodeling.
Vascular Remodeling in Hypertension
The predominant hemodynamic alteration in hypertension is increased total peripheral resistance, which is primarily determined by the small terminal arteries (<500 μm) and arterioles. [2] [3] [4] Several lines of evidence suggest that the increase in vascular resistance in hypertension is due primarily to rarefaction of small vessels and luminal narrowing due to vascular remodeling, with the later alteration predominating in most forms of hypertension. 3, 4 In essential hypertension, the resistance vessels undergo adaptive changes that are characterized by reduced lumen and increased media/lumen ratios. 3 This remodeling of vessel geometry serves to normalize wall stress, but also increases basal vascular reactivity, amplifying the vascular response to vasoconstrictors and thereby perpetuating hypertension. 2, 4 The remodeling of resistance vessels in essential hypertension appears to be due to rearrangement of the wall material around a smaller lumen, without a net gain in media crosssectional area or in the size or number of smooth muscle in the media. 2, 3 This type of remodeling is known as eutrophic remodeling ( Fig. 71.1 ). In other types of hypertension such as in renal hypertension, the remodeling process involves hypertrophy and possibly hyperplasia, as well as extracellular matrix accumulation triggered by Ang II and other growth factors, 67 leading to hypertrophic remodeling ( Fig. 71.1 ), which is a process of active growth of the vessel wall that is characterized by increased cross-sectional areas. This type of remodeling is seen in hypertension induced by the administration of deoxycorticosterone acetate and a high-salt diet [deoxycorticosterone acetate (DOCA) salt], and is associated with increase in the steady-state levels of TGF-β 1 and PDGF receptor gene expressions in the aorta. 68, 69 However, some investigators have argued that the term remodeling should strictly be used to describe structural rearrangement of the vessel wall without any increase in wall cross-sectional area.
A myriad of recent studies have focused on deciphering the molecular mechanisms involved in hypertension-induced vascular remodeling. Although a large percentage of these studies have been carried out in cell culture systems, the emerging picture is that vascular remodeling is regulated by an intricate mechanism involving the synergistic activation of multiple signal transduction pathways by growth factors and hemodynamic forces. 14, 15, 37, 70 It is now clear that reactive oxygen species generated by pro-oxidant enzyme systems such as reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase, and uncoupled eNOS play an essential role in activating these signaling pathways and in triggering the sequelae of events that culminate in remodeling of the vessel wall. 8, 12, 40, [70] [71] [72] [73] [74] [75] [76] Apoptosis, infl ammation, and extracellular matrix remodeling have all been considered key effector elements of vascular remodeling, but their role in hypertension-induced vessel remodeling remains controversial. 2, 12, 13, 77 In principle, apoptosis and infl ammation could be triggered by a variety of hypertensive stimuli including growth factors and reactive oxygen species (ROS). 2, 10, 40, 67, 72, 73 Regarding apoptosis, enhanced rate of apoptosis has been reported in the aorta of DOCA salt and spontaneously hypertensive rats (SHRs) compared to normotensive controls 78, 79 (reviewed elsewhere 2 ). Furthermore, cultured vascular smooth muscle cells (VSMCs) from hypertensive animals are more prone to apoptosis than cells from normotensive animals. 80 A combination of growth and apoptosis has been suggested to mediate eutrophic remodeling. 2, 3, 81 However, the rate of apoptosis in resistance arteries of SHRs has been reported to be lower than in normotensive animals, 82 thus raising doubts about the role of apoptosis in this type of vessel remodeling, at least in this genetically hypertensive animal model. The mechanisms initiating apoptosis of VSMCs in hypertension have not been fully elucidated, but appear to involve ROS and growth modulators such as angiotensin and NO. 40, 71, 72, 83 The role of infl ammation in hypertension-mediated remodeling is also controversial. ROS and Ang II, via its Inward Outward Hypotrophic Eutrophic Hypertrophic FIGURE 71.1. Potential outcomes of vascular remodeling. Remodeling may be eutrophic, in which case the wall materials are rearranged without a net increase in media cross-sectional area. In hypertrophic remodeling, there is net increase in media cross-sectional area through hypertrophy and hyperplasia of the media vascular smooth muscle cells and possibly fi broblasts and vascular progenitor cells from the adventitia. In hypotrophic remodeling, there is a net decrease in media cross-sectional area through loss of cells via apoptosis. Remodeling may be inward in which there is a reduction in lumen diameter, or outward, in which the lumen diameter is increased. In hypotrophic remodeling the media-lumen ratio is decreased, whereas in hypertrophic remodeling the wall-lumen is increases. effect on ROS production, activate the transcription factors nuclear factor (NF)-κB and AP-1, which regulates the transcriptional activity of a number of redox sensitive genes involved in the infl ammatory response. 13, 14, 40, 73, 74 Among these are adhesion molecules such as vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM), cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and chemokines such as monocyte chemoattractant protein-1 (MCP-1), which participate in the recruitment and infi ltration of infl ammatory cells into the vessel wall. 10, 39, 43 For example, hypertensive rats harboring the human renin and angiotensinogen transgenes showed increased adhesion molecule expression and avid infi ltration of infl ammatory cells in the kidney and heart vascular beds, 84 thus suggesting a role of Ang II in triggering infl ammatory events in these vascular beds. However, the role of Ang II in promoting infl ammation in other resistance vessels during development of hypertension is not known.
In addition to alterations in cell growth, vascular remodeling in hypertension involves changes in the extracellular matrix. 2 Extracellular matrix remodeling in hypertension involves both synthesis and breakdown of matrix components by matrix metalloproteinases (MMPs). Several studies have demonstrated the accumulation of extracellular matrix proteins in hypertensive animal models. Collagen I, III, and fi bronectin levels are increased in vessels from SHRs, DOCA salt-and Dal salt-sensitive hypertensive rats, [85] [86] [87] [88] [89] [90] [91] and in humans with essential hypertension. 92 The increase in collagen content in the extracellular matrix contributes to the increased stiffness commonly seen in arteries from hypertensive animals. Angiotensin II plays a dominant role in stimulating collagen production by smooth muscle cells via activation of angiotensin type 1 (AT1) and angiotensin type 2 (AT2) receptors. 93, 94 The mechanism involves activation of the mitogen-activated protein kinase/ERK pathway and the participation of autocrine mechanisms mediated by TGF-β and PDGF. 95 The accumulation of extracellular matrix proteins in hypertensive vessels may be partly associated with decreased MMP activity. The activities of several MMPs were reported to be decreased in mesenteric arteries of young SHRs before the onset of hypertension, 96 leading to decreased collagen degradation.
Vascular Remodeling in Atherosclerosis
Atherosclerosis is now widely recognized as an infl ammatory disease. 39, 97 Infl ammatory processes play a pivotal role in atheroma formation, and endothelial dysfunction plays an essential role in the mediating the infl ammatory response triggered by hyperlipidemia. [6] [7] [8] 39, 97 The dysfunctional endothelium expresses VCAM and other adhesion molecules, which help recruit leukocytes, thus initiating the process of infl ammation of the vessel wall. 12, 39 The induction of VCAM is triggered by the infl ammatory response mounted by the modifi ed lipoproteins that lodge in the subintimal space. The mechanisms of induction are transcriptional, regulated by the redox-sensitive transcription factor NF-κB, which is activated by upstream signaling mechanisms that are sensitive to ROS and cytokines such as TNF-α. The monocytes adhering to the activated endothelium then migrate into the subintimal space by diapedesis. 13, 39, 97 The migration of monocytes requires a chemokine gradient that is mediated by MCP-1, produced by activated vascular smooth muscle cells in the media; MCP-1 interacts with its cognate receptor CCR2, which is expressed in the diapedesing monocytes. Once in the subintimal space, the infi ltrating monocytes acquire the properties of macrophages and express scavenger receptors (SRA) and CD36, which take up modifi ed lipoprotein particles, becoming foam cells in the process and forming the fatty streak, a hallmark of the developing atherosclerotic lesion. 39, 97 The foam cell is a secretory factory, producing a variety of ROS, proinfl ammatory cytokines, growth factors, and MMPs, which not only aggravate the infl ammatory state of the vessel wall but also stimulate the migration and proliferation of smooth muscle cells from the media and possibly fi broblasts and vascular progenitor cells from the adventitia and bone marrow into the subintimal space. [19] [20] [21] 39, [98] [99] [100] In the subintimal space, the migrated smooth muscle cells and other vascular progenitors proliferate to form a neointima and a fi brous cap that covers the developing atheroma, preventing it from contact with the blood. 39, 43, 97 The process of smooth muscle cell migration is aided by digestion of the extracellular matrix by MMPs. However, as the lesion progresses, the proinfl ammatory state of the atheroma leads to enhanced extracellular matrix degradation and accentuated apoptosis of smooth muscle forming the fi brous cap, leading to thinning of the cap and plaque instability. 39, 97, 101 The unstable plaque may eventually rupture, exposing the highly thrombogenic subendothelial contents of the atheroma, resulting in thrombus formation and vessel occlusion. 101 It is now known that the plaque undergoes a dynamic process of remodeling associated with matrix turnover and vascular cell proliferation and apoptosis, [102] [103] [104] [105] [106] which ultimately determines the stability of the plaque. 101 Vascular smooth muscle proliferation is a prominent and essential component of atherosclerosis development. [41] [42] [43] 97 Although avid VSMC proliferation in the plaque leads to stenosis of the vessel, VSMC proliferation is also essential for plaque stability. 2, 39, 43, 97, 101, 104, 105 Thus, new therapies for atherosclerosis should aim at achieving a balance between VSMC proliferation and stabilization of the plaque, such that reduction of lumen stenosis is not achieved at cost of plaque vulnerability. Considering the central role of ROS and infl ammation in atheroma formation and in neointimal smooth muscle proliferation, it seems logical that reducing oxidative stress and infl ammatory processes should be a primary therapeutic target in atherosclerosis. 97 For example, lipidlowering drugs such as statins (HMG CoA inhibitors) and fi brates, as well as Ang II antagonists such as ACE inhibitors and angiotensin receptor antagonists exert benefi cial effects in treatment of atherosclerosis that are largely unrelated to reduction of lumen stenosis. 97 Instead, these drugs appear to exert pleiotropic effects in the vessel wall by reducing infl ammation and oxidative and inhibiting the sequence of pathologic events triggered by these stimuli, 29 including endothelial dysfunction and VSMC proliferation.
Vascular Remodeling in Vasculoprotective Disease
In response to injury induced by interventional procedures such as balloon angioplasty and bypass grafting, a reparative process is activated that may lead to restenosis. Excessive vascular smooth muscle proliferation is the hallmark of vasculoprotective diseases, 33, 43, 107 leading to neointima formation and stenosis of the vessel or graft. Recent evidence suggests that circulating progenitor cells may also contribute to neointima development. 19, 22, 24, 25 The neointima provides a substrate for the development of atherosclerosis, which represents the terminal step in the pathologic process leading to transplant vasculopathy and in bypass graft failure. 43, 108 Given the central role of vascular smooth muscle proliferation in the pathogenesis of these diseases, it is not surprising that current and emerging therapies are focusing on strategies to inhibit cell proliferation. Prominent among these is the use of cytostatic agents to inhibit cell cycle entry, and several advances have been made in this direction with the introduction of drug-eluting stents capable of releasing cytostatic drugs such as rapamycin and paclitaxel. Cytotoxic strategies such as brachiotherapy have found less wide acceptance in clinical application. 109 Molecular therapies aimed at targeting specifi c cell-cycle regulatory molecules may provide new options for treatment of vasculoproliferative disease in the future, and proof-of-concept experiments have already provided validation of these strategies in animal models of vascular injury (reviewed elsewhere 43 ). The recent availability of methods for isolation and manipulation of endothelial progenitor cells and other adult stem cells provides yet another option for vascular repair following injury, and early animal studies provides support for the therapeutic potential of these adult stem cells in vessel repair and tissue engineering (reviewed elsewhere 34 ).
The development of restenosis involves cellular and noncellular events that may be arbitrarily divided into three phases (Table 71 .1), according to the sequence of events compiled from studies of several animal models and analysis of human histologic, angiographic, and intravascular ultrasound data.
Phase I: Acute Injury and Release of Mediators
Balloon angioplasty causes local vascular injury, including endothelial denudation, rupture of the internal elastic lamina, lysis of some medial VSMCs, and fracture of the atherosclerotic plaque. With further stretching, medial dissection may result in subsequent dilatation of the outer media and adventitia. Initiated by this mechanical injury, phase I is characterized by interaction of platelets and thrombin with the vessel wall (phase IA) and release of numerous biologically active mediators (phase IB). These events occur over minutes to hours after injury.
PHASE IA: ACTIVATION OF PLATELETS AND THROMBIN
Exposure of the subintimal layers and collagen to bloodborne elements leads to activation of the hemostatic system with extensive platelet deposition and fi brin formation. 110 Platelet aggregation is mediated by release of adenosine diphosphate, serotonin, thromboxane A 2 , fi brinogen, fi bronectin, and von Willebrand factor. Platelets make contact with subendothelial layers and other platelets by glycoprotein Ib and IIb/IIIa receptors. Interestingly, the thickness of the deposited platelet layer and the predisposition to thrombus formation are proportional to the amount of subendothelial injury. With severe injury, thrombus formation ultimately may contribute to an organized fi brocellular plug. These initial events begin within minutes after injury, peak 4 to 12 hours later, and are sustained for at least 24 to 48 hours. Thrombin generation (through the intrinsic and extrinsic pathways) can promote platelet aggregation and fi brin production. Thrombin generation by apoptotic VSMCs has also been described. 111 This may be important in light of reports describing signifi cant VSMC apoptosis immediately after balloon injury. 112, 113 Thrombin has been shown to stimulate growth factor release, VSMC proliferation, and alterations in extracellular matrix composition. 114, 115 Fibrin is also chemotactic for VSMCs in vitro. Therefore, the activation of thrombin and the coagulation cascade are likely to contribute to the development of neointimal hyperplasia.
PHASE IB: RELEASE OF GROWTH FACTORS AND CYTOKINES
A number of vasoconstrictors (e.g., thromboxane and serotonin) and mitogens are released by activated platelets, the most important of which are PDGF, epidermal growth factor, and TGF-β 1 . 116 As a chemotactic and mitogenic agent, PDGF is a potent stimulus to VSMC migration and proliferation. A polyclonal antibody to PDGF has been shown to reduce neointima formation in rats. Mechanical injury itself may lead to VSMC proliferation by resulting in denudation of the endothelium, with consequent loss of endothelium-derived growth inhibiting factors such as NO and prostacyclin and release of growth factors from the injured ECs and VSMCs.
Fibroblast growth factor appears to be one such mitogen for ECs and VSMCs. 117, 118 Reduction in the levels of these important inhibitors of VSMC growth and migration contributes to the initial process of neointima formation. 
Phase II: Smooth Muscle Replication and Infl ammation
The intermediate phase is characterized by initial activation and replication of medial VSMCs followed by migration of VSMCs from the media to the subintima (phase IIA). This process occurs over a period of time lasting days to weeks, and is followed by VSMC replication, initiating the development of neointimal hyperplasia (phase IIB), which may last weeks to months. Concomitant to these processes is the infi ltration of leukocytes brought into the area by cytokines and chemotactic agents as well as adhesion molecules and the proliferation of these infl ammatory cells (phase IIC).
PHASE IIA: MEDIAL SMOOTH MUSCLE CELL REPLICATION AND MIGRATION
Approximately 30% of medial VSMCs become activated within the fi rst few days after balloon angioplasty 119 by PDGF (released from platelets, macrophages, injured ECs, and VSMCs), thrombin, fi broblast growth factor (FGF) (from injured ECs and VSMCs), and other factors. These cells increase DNA synthesis, express the "synthetic" phenotype, and begin to replicate. 120, 121 With extensive injury, up to 30% of the medial VSMCs may migrate to the subintimal space 122 and replicate, usually beginning in the fi rst few days after angioplasty. 123 Although PDGF appears to be a principal growth factor stimulating cells to migrate, FGF, Ang II, and changes in the extracellular matrix (with expression of proteolytic enzymes) may also participate.
PHASE IIB: REPLICATION OF INTIMAL VASCULAR SMOOTH MUSCLE CELLS
This phase is characterized by "autoreplication" of VSMCs that have migrated to the intima. In humans, intimal hyperplasia can be detected by the second to third week and appears to plateau by the third to fourth month after coronary angioplasty. 121, 123 During this proliferative phase, intimal VSMCs, fi broblasts, and macrophages express autocrine and paracrine growth factors, including PDGF, FGF, insulin-like growth factor-I (IGF-I), TGF-β, and Ang II. These local factors play an important role in stimulating VSMC proliferation.
Phase III: Vascular Remodeling
An active process of extracellular matrix modulation occurs in restenosis. There is evidence of both matrix deposition and degradation. Fibroblast and infl ammatory cells contribute to these processes. As the intimal VSMCs lose their capacity to replicate, they also produce large amounts of extracellular matrix proteoglycan. Experimental and clinical studies, especially those using intravascular ultrasound, have suggested that a reduction in vessel caliber resulting from vascular remodeling may play an important role in the narrowing of the restenotic segment. 124 Although metalloproteinase inhibitors have been shown to affect the early response after balloon injury by infl uencing VSMC cell migration, they have not been shown to affect restenosis. 125 
Role of Progenitor Cells in Atherosclerosis and Vasculoproliferative Disease
In addition to resident VSMC and fi broblasts from the adventitia, recent evidence suggests that circulating smooth muscle progenitor originating in the bone marrow may also contribute to the pathogenesis of vascular remodeling in atherosclerosis and vasculoproliferative disease (reviewed elsewhere 19 ). Using mouse models of postangioplasty restenosis, graft vasculopathy, and hyperlipidemia, Sata and colleagues 22 showed that hematopoietic stem cells from the bone marrow can transdifferentiate into smooth muscle cells. Furthermore, these authors reported that the bone-marrow-derived vascular progenitors gave rise to the majority of the smooth muscle cells participating in neointima formation and graft atherosclerosis; however, the relative percentage contribution of these cells to remodeling has been questioned by others 20, 21, 126 (reviewed elsewhere 19 ). Circulating smooth muscle progenitors have also been reported in human peripheral blood after culture of mononuclear cells from the buffy coat in medium containing PDGF-BB. 127 More recently, Caplice and colleagues 23 reported the presence of donor-derived smooth muscle cells in autopsy specimens of atherosclerotic lesions collected from patients who had previously undergone gender mismatched bone marrow transplantation for treatment of leukemia. The authors reported signifi cant recruitment of donor-derived cells to the sites containing atherosclerotic lesions but not in healthy vessels.
In contrast, to these fi ndings, Hu and colleagues 20 did not fi nd any evidence of bone-marrow-derived progenitors in vein graft atherosclerotic lesions. In these studies, the authors isografted segments of the vena cava to the carotid artery between transgenic mice expressing the bacterial βgalactosidase gene (LacZ) in vascular smooth muscle cells (SM-LacZ) or in all tissues (ROSA26) and wild type. The investigators reported the presence of β-galactosidase in all neointimal and atherosclerotic lesions in all of the chimeric vein grafts made between the LacZ transgenic mice and the wild type. Further characterization of the cells in the lesion revealed that approximately 60% of the cells originated from the donor vessel. The possibility that the cells in the lesion originated in the bone marrow was excluded by the absence of β-galactosidase positive cells in atherosclerotic lesions of chimeric mice that had undergone lethal irradiation and bone marrow reconstitution with β-galactosidase marked cells. 20 These investigators subsequently reported that the adventitia may be the source of progenitor cells accumulating in the atherosclerotic lesions. 21 The authors found that the adventitia of aortic roots yielded an abundance of cells expressing cell surface stem cell markers such as Sca-1, c-kit, CD34, and Flk-1. Furthermore, culture of these cells gave rise to heterogeneous outgrowths that could be directed to specifi c vascular lineages under defi ned growth conditions. 21 They further demonstrated that transplantation of the adventitia-derived Sca-1 + cells from ROSA26 mice to the adventitial side of vein grafts in apolipoprotein E (ApoE)-defi cient mice resulted in migration of the Sca-1 + cells to the atherosclerotic lesion where they differentiate into smooth muscle cells (SMCs) that populate approximately 30% of the neointima. 21 However, the ontogeny of the adventitial cells is not known. It has not been identifi ed whether these cells are bona fi de resident vascular precursor cells, or whether they represent bone-marrow-derived progenitors that have migrated earlier in development to take up residence in the adventitia. Others have reported that bone marrow progenitors do not contribute signifi cantly to endothelial regeneration in transplant arteriosclerosis. 26 This fi nding is intriguing, in light of the fact that vascular injury has been reported to be a strong stimulus for recruitment and homing of bonemarrow-derived endothelial progenitor cells. The role of progenitors in the pathogenesis of human vascular disease and in vessel repair has not yet been established.
Molecular Mechanism of Vascular Remodeling
It is now known that the adaptations of the vessel wall to physiologic and pathologic alteration in hemodynamic forces share several mechanisms in common, namely apoptosis and proliferation of vascular cell types, extracellular remodeling, and rearrangement of wall materials to accommodate the new hemodynamic status. However, whereas the adaptations of the vessel wall to physiologic alterations in pressure and fl ow remain within the realm of homeostasis, the changes that occur in response to abnormal changes in hemodynamic forces in vascular disease become maladaptive in the face of pervasive oxidative and infl ammatory stresses, which lead to endothelial dysfunction and dysregulation of apoptosis and growth processes.
Endothelial Dysfunction
Endothelial dysfunction is the earliest event that signals the onset of cardiovascular disease. This alteration in endothelial function is characterized by decreased vasodilation and increased proinfl ammatory and prothrombotic activity of the endothelial cells ( Fig. 71 .2). In normal conditions, NO exerts multiple effects that are essential for maintenance of vessel wall homeostasis. 5 These include vasodilation, inhibition of vascular smooth muscle proliferation and migration, and downregulation of infl ammatory and adhesion molecules. However, risk factors for cardiovascular disease induce oxidative stress, which plays a major role in endothelial dysfunction. 6, 7 Reactive oxygen species accelerate the catabolism of NO and activate redox-sensitive transcription factors such as NF-κB, which upregulate the transcription of various proinfl ammatory genes, chemokines, adhesion molecules, and prothrombotic factors in the endothelium. 8, 11, 13, 43, 72, 73, 75, 76, 127 The activated endothelial cells produce excessive amounts of ROS and adhesion molecules, resulting in increased vascular tone, microvascular dysfunction, and enhanced leukocyte adhesion. 73 Thus, reduced NO bioactivity provides a link between oxidative stress, endothelial dysfunction, and the pathogenesis of cardiovascular disease.
Role of Oxidative Stress
Reactive oxygen species play a major role in the initiation and progression of cardiovascular diseases such as hypertension and atherosclerosis. 8, 71, 72 In the vascular wall, ROS is produced by multiple sources, including the endothelial cells, VSMCs, and infi ltrating infl ammatory cells. 71 The pro-duction of ROS in excess in the vascular wall overwhelms endogenous antioxidant systems, resulting in oxidative stress. Within the vessel wall, the predominant ROS are the free radical superoxide (O 2 .− ) and hydrogen peroxide (
.− is produced enzymatically primarily by reduced nicotinamide adenine dinucleotide (NADH) oxidase and to a lesser extent by xanthine oxidase and myeloperoxidase. 71, 73, 74, 103 In addition, in the presence of oxidative stress eNOS becomes uncoupled due to inactivation of its cofactor tetrahydrobiopterin and generates ROS as well, further exacerbating oxidative stress. 8 
.− and can react with transition metals to form the highly reactive hydroxy radical (˙OH) species. 71 At physiologic concentrations, ROSs play essential roles as signaling molecules 72 and modulate a variety of physiologic functions in the vessel wall. However, when in excess, ROS exerts a series of deleterious effects that lead to impaired vascular function, including decreased NO production, stimulation of vascular cell migration, proliferation and apoptosis, cytokine and adhesion molecule production, infl ammatory cell adhesion, and extracellular matrix degradation (reviewed elsewhere 8, 71 ). All components of the vessel wall are affected by ROS. In the endothelial cells, oxidative stress uncouples NO synthase and stimulates adhesion molecule expression, culminating in endothelial dysfunction, whereas in the media, ROS promotes VSMC hypertrophy, proliferation, migration, and apoptosis. 2, 8, 12, 71, 72 These effects appear to be critically dependent on production of ROS by NADPH oxidase. 98 In addition, ROS activates the VSMC to express proinfl ammatory genes and chemokines, including TNF-α, IL-6, and MCP-1, 71 and ROS stimulates MMP production, which plays an essential role in matrix remodeling in vascular diseases. 71, 103 All of these effects of ROS in the cells of the vessel wall are central to the initiation and progression of hypertension, atherosclerosis, and vascular proliferative diseases. 8, 71 Role of Apoptosis Another central feature of vascular remodeling is apoptosis. 12 Apoptosis is involved in vessel remodeling during development and in response to physiologic changes in blood fl ow (reviewed elsewhere 37 ). In addition, apoptosis has been reported in hypertension, atherosclerosis, and neointima hyperplasia. 12, 43, 128, 129 The role of apoptosis in hypertensioninduced vascular remodeling remains controversial (reviewed elsewhere 2 ). Some evidence suggests that it may play a role in maintaining constant medial cross-sectional area during eutrophic remodeling of resistance arteries in essential hypertension by counterbalancing VSMC hyperplasia. 2 On the other hand, the rate of apoptosis was found to be reduced in young SHRs, suggesting that the decrease in apoptosis may contribute to the enhanced growth of the resistance vessels in these animals. 82 Apoptosis has also been documented in infl ammatory vasculoproliferative disease, 43, 128, 129 and several studies have reported apoptosis of VSMC in atherectomy specimens from atherosclerotic and restenotic vessels. 128, 129 Apoptosis assumes particular importance in atherosclerosis, where it may contribute to plaque instability and rupture (reviewed elsewhere 12, 97 ). Vascular smooth muscle cell apoptosis is pronounced in advanced atherosclerotic plaques, particularly in the shoulder regions of the Nitric oxide production is decreased and the balance between vasodilator and vasoconstrictor moieties such as endothelin and thromboxanes is disrupted, leading to vasoconstriction. The endothelial cell becomes "activated" and synthesizes cell surface adhesion molecules such as selectins and integrins, which increase leukocyte and platelet adhesion and thrombus formation. The loss of growth inhibiting mediators from the endothelium triggers the activation and migration of vascular smooth muscle into the intimal space where they proliferate to form the neointima. In time the infi ltration of infl ammatory cells into the intimal space and accumulation of oxidized low-density lipoprotein (LDL) results in the formation of the atherosclerotic lesion. CaM, calmodulin; ECM, extracellular matrix; FAD, fl avin adenine dinucleotide; ICAM, intercellular adhesion molecule; NADPH, reduced nicotinamide adenine dinucleotide phosphate; TBx, thromboxane; TH4, tetrabiopterin; VCAM, vascular cell adhesion molecule; VSMC, vascular smooth muscle cells. plaque. 12, 97, 102, 103, 105 It is believed that the reduced plaque cellularity associated with VSMC apoptosis is a major contributing factor leading to plaque rupture. 97 In addition to its effects on plaque stability, the apoptosing VSMCs stimulate infl ammatory cell infi ltration, thus aggravating the proinfl ammatory microenvironment of the atherosclerotic plaque. 97, 130, 131 Endothelial cell apoptosis also appears to contribute to the pathogenesis of atherosclerosis, and increased endothelial cell turnover is seen in areas prone to atherosclerotic lesion development. 102, [132] [133] [134] The apoptosing endothelial cell becomes highly proadhesive, thus increasing the occurrence of thrombus formation. 132 Avid apoptosis has also been documented in animal models of vascular injury. 43, 128, 129 In balloon-injured arteries apoptosis occurs in two waves: an early intense wave that occurs within hours of the injury, leading to markedly reduced cellularity of the vessel wall, and a late-onset protracted response occur within days to weeks. 128 It could be argued that in the setting of postangioplasty restenosis, apoptosis may actually be benefi cial by providing a mechanism to limit excessive VSMC proliferation. However, the massive loss of medial VSMCs during the fi rst wave of apoptosis may in fact mount an enhanced healing response to counteract the cell loss, thereby exacerbating neointima hyperplasia rather than reducing it. Indeed, as with endothelial cells, the apoptosing VSMCs release a variety of proinfl ammatory cytokines that could stimulate proliferation.
A variety of physical and humoral factors play a role in regulating apoptosis in the vessel wall. Cell-cell and cellmatrix interaction and shear stress play an essential role in survival of endothelial cells, and loss of cell-cell contact and reduction in shear stress promote endothelial cell apoptosis. 12, 102, 135 Extracellular matrix protein such as fi bronectin, vascular endothelial (VE)-cadherin, and growth factors such as vascular endothelial growth factor (VEGF) and FGF also promote endothelial survival, whereas decreases in shear stress or endothelial growth factor defi ciency lead to apoptosis. 12, 102, [135] [136] [137] On the other hand, ROS and proinfl ammatory cytokines such as TNF-α and IL-6 induce endothelial cell apoptosis. 102 In VSMCs, growth factors such as PDGF-BB, FGF-2, TGF-β 1 , and IGF-I and cell-cell and cell-matrix interactions serve as survival signals, 97, 102, 107 whereas ROS, oxidized low-density lipoprotein (LDL), and proinfl ammatory cytokines induce apoptosis. 12, 97 Interestingly, NO, when produced at high levels by induction of inducible nitric oxide synthase, leads to marked apoptosis. In fact, it is thought that this is the primary mechanism by which proinfl ammatory cytokines induce VSMC apoptosis in the vessel wall. 12, 83, 102 Growth The vessel wall produces several growth-promoting factors, such as PDGF, basic fi broblast growth factor (bFGF), IGF-I, and IL-1. [138] [139] [140] Both the A and the B chains of PDGF are synthesized by the endothelium, VSMCs, and macrophages. All three dimeric isoforms of PDGF (AA, AB, BB) may be produced and secreted in the vessel wall. Production of either the AB or the BB isoform promotes VSMC migration and proliferation and may play a role in some forms of vascular remodeling (Table 71 .2).
The cytokine IL-1 is expressed by endothelium and may play a role in vascular remodeling associated with infl ammation. Endothelial IL-1 expression is increased by proinfl ammatory substances, such as endotoxin and TNF. Administration of IL-1 to cultured VSMCs induces proliferation only during prostaglandin synthesis blockade. 141 The IL-1 proliferative response appears to be mediated by the induction of autocrine production of PDGF AA. 142 Studies of cultured ECs suggest that IL-1 inhibits EC proliferation and angiogenesis. Interestingly, increased autocrine expression of IL-1 is associated with EC senescence. This decrease in proliferative capacity can be reversed by antisense oligonucleotides directed against IL-1 production. 143 The growth factor IGF-I participates in the regulation of EC and VSMC growth. Several reports suggest that it plays an autocrine growth-promoting role in microvascular ECs. 144, 145 In VSMCs, IGF-I acts as a growth progression factor for quiescent cells rendered "competent" to proceed through the cell cycle toward DNA synthesis by growth factors such as PDGF and bFGF. 146 In the absence of other growth factors, IGF-I promotes VSMC hypertrophy and matrix production. 147 The growth effects of IGF-I are modulated by IGF binding proteins that may either inhibit or potentiate its activity, depending on experimental conditions. 148 Basic FGF is a potent autocrine growth factor for ECs and a VSMC mitogen. 149, 150 In vitro studies with neutralizing antibodies suggest that bFGF plays a critical role in EC proliferation, cell migration, cell invasion, matrix alterations, and angiogenesis. 140, 150 It lacks a classic signal peptide and is pri-marily intracellular but can be recovered from the extracellular matrix. 140 The peptide contains a nuclear localization sequence that, when deleted by site-directed mutagenesis, abolishes its mitogenic properties. These fi ndings suggest that bFGF may behave as an intracrine growth factor. In addition to these intracellular actions, bFGF is bound to heparin sulfate within the matrix. The matrix acts as a reservoir that binds bFGF released during cell wounding/lysis and may release it in response to proteases, such as heparinitase, released by platelets and leukocytes. 140 Although regulation of its function is still poorly defi ned, bFGF has profound effects on vascular structure.
Vascular endothelial growth factor is an endothelialspecifi c growth factor that has no effect on VSMCs, fi broblasts, or other vascular cells. It has been shown to induce EC proliferation, stimulate cell migration, 151, 152 and inhibit apoptosis. 153, 154 In vivo, VEGF plays a central role in vasculogenesis and angiogenesis in response to tissue hypoxia. 155 Because of the latter effect, VEGF is gaining increasing attention as a therapeutic tool to induce postnatal angiogenesis in ischemic conditions. 156 In addition to growth promoters, the vessel wall also produces growth inhibiting factors. Campbell and Campbell 157 and Castellot and colleagues 158 have observed that confl uent ECs secrete growth-inhibitory substances that appear to promote the expression of certain characteristics exhibited by the most quiescent, differentiated-appearing VSMC phenotype. Other studies suggest that heparin sulfate produced by ECs inhibits VSMC growth and migration. 159, 160 Studies demonstrate that the endothelium VSMC and macrophage also produce TGF-β 1 . [161] [162] [163] This multifunctional growth factor promotes angiogenesis and inhibits EC proliferation and migration. 162, 164, 165 Transforming growth factor-β 1 has a bifunctional effect on VSMC growth in that it either inhibits mitogen-induced proliferation or stimulates VSMC proliferation that is mediated by the autocrine production of PDGF AA. 138, 139, 166 Based on the available data, we would speculate that TGF-β 1 and heparin participate in vascular remodeling. Factors such as TGF-β 1 may be particularly important in structural changes in which the vessel lumen size decreases or blood vessels undergo rarefaction or regression, that is, settings in which cell loss and matrix production are important.
Classic mitogens, such as PDGF and epidermal growth factors, have vasomotor effects, whereas vasoactive substances, such as Ang II and serotonin, can be mitogenic, 167, 168 suggesting that vasoactive-agents and growth factors share overlapping signal transduction pathways. In confl uent quiescent VSMCs in culture, Ang II induces cellular hypertrophy 169 associated with increased messenger RNA (mRNA) levels of proto-oncogenes c-fos, c-jun, and c-myc, and the autocrine growth factors PDGF A chain, bFGF, and TGF-β 1 . 170 These autocrine growth factors may mediate angiotensininduced hypertrophy.
On the other hand, Ang II-induced TGF-β 1 production is responsible for modulating the mitogenic effect of PDGF and bFGF because blockade of the TGF-β 1 effect by specifi c antibodies or antisense oligonucleotide resulted in Ang IIinduced DNA synthesis and cell proliferation. 170, 171 Thus, angiotensin is a bifunctional growth factor able to activate proliferative (PDGF, bFGF) and antiproliferative (TGF-β 1 ) cellular mechanisms simultaneously. The latter is dependent on the activation of a protein kinase C (PKC)-dependent pathway. In addition to its direct effects on VSMCs, Ang II also can interact with other growth factors in the vessel wall. Angiotensin may potentiate serum-, bFGF-, and PDGFinduced DNA synthesis. 172 These fi ndings suggest that angiotensin may modulate the proliferative response to autocrine/paracrine growth factors. Moreover, alterations in VSMC phenotype may modulate the Ang II-induced growth response by altering the susceptibility to proliferative versus antiproliferative factors.
Similar to the response to Ang II, we and others have shown that endothelin also can induce an increased expression of c-myc in association with VSMC proliferation. 173 Growth-promoting effects on VSMCs also have been described for many other vasoconstrictors, for example, norepinephrine, thromboxane, leukotrienes, vasopressin, substance K, and serotonin. 168, [174] [175] [176] [177] The sympathetic nervous system appears to exert a trophic effect on the vasculature to promote growth and remodeling. 177, 178 Removal of this neural input attenuates the structural responses of the vas-culature. The growth effects of catecholamines may be mediated by the autocrine production of PDGF AA. 179 The growth effects of vasoactive substances are also associated with effects on VSMC migration. Ang II, serotonin, and norepinephrine have been shown to enhance cell migration as well as stimulate growth. 180, 181 In contrast, endogenous vasodilators that activate adenylate cyclase, such as prostacyclin, prostaglandin E 2 , and adenosine, or vasodilators that activate guanylate cyclase, such as NO, atrial natriuretic peptide and adrenomedullin, inhibit VSMC growth. [182] [183] [184] [185] [186] The effects of vasodilators on VSMC migration are not well defi ned.
The effect of vasoactive substances on EC growth is not as well characterized. It has been reported that catecholamines, histamine, and adenosine enhance serumstimulated cell proliferation. [187] [188] [189] The growth stimulation of adenosine appears to be potentiated in the setting of hypoxia. 189 Conversely, activation of guanylate cyclase inhibits the proliferation of conduit vessel endothelium, and protein kinase C activation inhibits microvascular endothelial proliferation. 190, 191 The effects on endothelial growth usually are associated with other functional changes, such as alterations in cell movement. It has been reported that Ang II, serotonin, norepinephrine, and histamine inhibit EC migration in vitro. 68, 69 
Signaling Mechanisms Involved in Remodeling
The mechanism involved in remodeling involves multiple signaling cascades and downstream transcription factors that function coordinately to activate a large number genes involved in regulation of growth, apoptosis, and extracellular matrix metabolism. 2, 3, [12] [13] [14] [15] 27, 28, 40, 43, 67, 71, 72, 106, 136, 137 These signaling mechanisms are activated by a variety of stimuli including mechanical stress (shear stress, stretch), ROS, growth factors, and cytokines. 14, 40, 67, 68, [71] [72] [73] [74] [75] [76] [77] [98] [99] [100] Stretch of the vessel wall caused by sustained increase in intravascular pressure acts on all layers of the vessel wall, whereas shear stress acts predominantly on the endothelium in response to changes in blood fl ow. 1, 14, 45, 135 Stretch activates several growth promoting signaling pathways, including focal adhesion kinase (FAK) pathway, the mitogen-activated protein kinase (MAPK) cascade, and the renin-angiotensin system within the vessel wall. 2, 13, 71, 72, 75 Integrins at the cell surface are the likely sensors of stretch and shear stress (mechanosensors), and stretch-sensitive nonselective cation channels, and possibly potassium channels, function as transducers, converting the mechanical stimulus into activation of the biochemical pathways that lead to stimulation of growth and remodeling of the vessel wall. 14 The process of transmission of mechanical stress begins the clustering of α 5 β 1 integrin and gathering of the cytoskeletal proteins talin and vinculin to form focal adhesions and stress fi ber that anchor to the cytoskeleton. FAK is recruited to the focal adhesion and becomes tyrosine phosphorylated. The small G protein RhoA is also involved in the formation of focal adhesion and stress fi bers by promoting the phosphorylation of FAK and paxillin as well as promoting actin fi lament polymerization. The increase in mechanical stress activates the tyrosine kinase c Src, which translocates to the focal adhesions, where it phosphorylates FAK, which becomes activated in the process. The MAPK pathway is the primary signaling mechanisms by which mechanical stress and growth factors regulate expression of the genes involved in growth and remodeling of the vessel wall. All three MAPK pathways (MAPk, JNK, p38) are involved. 14 In endothelial cells MAPK is the predominant cascade activated by increases in shear stress, whereas both ERK and JNK are activated in response to stretch. 14 In addition, Akt has been found to be activated in endothelial cells in response to shear stress, where it stimulates eNOS phosphorylation and activity and promotes endothelial cell survival and migration. [192] [193] [194] Platelet-derived growth factor-β appears to play an essential role in activating the MAPK cascade in response to mechanical stress and Ang II, and the nonreceptor tyrosine kinase c-Src plays an essential role in this process. 2, 3, 14 Several other G protein and PKC-mediated mechanisms are also involved in activation MAPK pathway in response to mechanical stress. Upon phosphorylation by upstream kinases, the end terminal ERK1/2 kinase translocates to the nucleus, where it phosphorylates multiple transcription factors involved in cell cycle regulation and protein synthsesis. 14 Many of the common growth promoting factors in the vasculature including Ang II and PDGF appear to exert their effects, at least in part, via the MAPK pathway as well. 98, 101 However, non-MAPK mechanisms may also be involved. Some factors such as Ang II and proinfl ammatory also produced ROSs, which serve as intermediate messengers to activate multiple signaling pathways including proximal tyrosine kinases such as c-Src, which appears to play a major role in PDGF receptor and EGF receptor transactivation by Ang II, leading to downstream activation of the low molecular weight guanosine triphosphate (GTP) binding protein, which subsequently activated the MAPK pathway. 71, 72, [98] [99] [100] [101] In addition, ROSs also directly stimulate MAPK, including ERK 1/2, p38 MAPK, JNK/SAPK, and Akt. The activation of these signaling cascades by ROSs leads to the upregulation of multiple redox sensitive genes involved in growth infl ammation and extracellular remodeling of the vascular wall. The ROSs may also bypass these signaling cascades to directly regulate the activity of redox sensitive transcription factors such as NF-κB, Egr-1, and AP-1. [72] [73] [74] [75] [76] 
Therapeutic Strategies for Vascular Remodeling

Drug Therapies
Several of the currently used antihypertensive and cholesterol-lowering drugs have been shown to have benefi cial effects in reversing the structural changes associated with vessel remodeling in hypertensive patients and in plaque stabilization in patients with atherosclerosis. 26, 27, 29, 97 Among the most successful drugs in this regard are the ACE inhibitors and angiotensin receptor blockers, 27 peroxisomeproliferator-activated receptor (PPAR) agonists, 28 and HMG CoA inhibitors. 29 Hypertensive patients on long-term ACE inhibitor therapy consistently show improved endothelial function and reduced remodeling in small arteries. 27, 195, 196 Interestingly, treatment with the beta-blocker atenolol failed to improve endothelial function and vessel remodeling despite similar reduction in blood pressure. 196 Similar results were seen with the angiotensin receptor blocker losartan. 197 The mechanisms involved in improving endothelial function and vessel remodeling after treatment with blockers of the renin-angiotensin system are not known, but likely involve inhibition of the growth-promoting, profi brotic, and proinfl ammatory actions of Ang II.
Another drug family that has been found to have beneficial effects in vessel remodeling is the peroxisome-proliferator activator receptor agonists belonging to the fi brate and glitazone family (reviewed elsewhere 28 ). These drugs exert antiinfl ammatory, antioxidant, and antiproliferative effects in the vessel wall and are able to antagonize the actions of Ang II in vivo. 28 Treatment with these drugs improves the lipid profi le and reduces the concentrations of circulating infl ammation markers such as C-reactive protein (CRP) and CD40L in diabetic patients. 198, 199 Rosiglitazone has been reported to reduce endothelial activation in nondiabetics with coronary artery disease. 198 Other studies have shown that rosiglitazone treatment signifi cantly improved endothelial function and reduced BP and fasting insulin levels in patients who met the criteria of metabolic syndrome. 200 Thus, these studies suggest that PPAR agonists are useful in reducing atherogenic and infl ammatory effects and improving endothelial function in patients with diabetes or coronary artery disease.
Another family of drugs that has been found to have potentially benefi cial vasculoprotective effects is the HMG CoA inhibitor family of drugs called statins. 29 It is now recognized that in addition to their cholesterol-lowering effect, these drugs have pleiotropic effects in the vessel wall that may lead to plaque stabilization and reduction of vascular remodeling [201] [202] [203] (reviewed elsewhere 29, 97 ). Some of these effects include improvement of endothelial vasodilation, a phenomenon that is possibly due to the ability of statins to stimulate Akt and phosphorylation of eNOS. 204, 205 In addition statins exert antiinfl ammatory effects. 201 Statins also stimulate endothelial progenitor cell mobilization, and this may accelerate endothelial recovery and decrease restenosis following balloon angioplasty. 206 On the other hand, statins also promote angiogenesis, and this could potentially accelerate plaque development (reviewed elsewhere 207 ).
Percutaneous Coronary Revascularization
With the number of percutaneous transluminal coronary angioplasty (PTCA) procedures growing exponentially over the last decade, physicians and researchers were urged to fi nd effective strategies to prevent restenosis. The introduction in the clinical arena of the stent represented a major advancement in the prevention of the occurrence of restenosis ( Fig.  71.3 ). This device can in fact abolish both elastic recoil and vessel remodeling, consequently reducing restenosis of the treated lesion. Nevertheless, in-stent restenosis exists and the incidence may vary from 8% to as high as 80% at 6 months, depending on both anatomic and clinical risk factors (reviewed elsewhere 33 ). The main determinant of in-stent restenosis is the neointimal formation due to exaggerated VSMC proliferation. 31, 33, 104 Mechanical approaches have proved too simplistic to prevent in-stent restenosis. Interfering with molecular cell proliferation is a more effective manner of limiting neointimal formation. The development of drug-eluting stents (DESs) has been a major breakthrough in this direction, and numerous clinical trials have in fact demonstrated that DESs strikingly reduce the incidence of in-stent restenosis compared with bare metal stents. 30, 33 Some drug can be loaded directly onto the metallic surface of the stent. 32, 33 However, biomedical engineering progress has facilitated the development of specifi c coating matrixcontaining drugs that are released in situ after stent deployment. Different polymers have been tested so far and many more are currently under investigation. 30, 33, 109 The selection of a noninfl ammatory, inert coating has been a challenge only partially resolved. There is a long list of candidate substances for stent coating in continuous expansion. These substances can be categorized as organic, inorganic, biodegradable, nonbiodegradable, or synthetic. 31, 32 The ideal antirestenotic agent for local delivery should have antiproliferative effects preserving the vascular healing of the vessel.
Many biologic agents have been proposed as antiproliferative drugs but so far only two DESs have demonstrated clinical effi cacy in large randomized trials: sirolimus-(Rapamue; Wyeth-Ayerst Laboratories) and paclitaxel-eluting stents (Taxol; Bristol-Myers Squibb). Sirolimus is a macrolide antibiotic that inhibits VSMC proliferation by binding an intracellular protein receptor, the FKBP12. The sirolimus-FKBP12 complex binds to the mammalian target of sirolimus, a signal transduction protein (mTOR), which is upregulated in human neointimal VSMCs 208 and inhibits its activation. The inhibition of mTOR ultimately prevents cell cycle progression at the G 1 -to-S phase transition. 208, 209 Sirolimus increases levels of the cyclin-dependent kinase inhibitor p27 Kip1 that binds and inactivates the cyclin E/cdk2 complex and inhibits cell-cycle progression. In fact, when inactivated, the cyclin E/cdk2 complex cannot phosphorylate the retinoblastoma protein and leads to its dissociation from the transcriptor factor E2F, which is essential to regulate the expression of genes encoding proteins required for the G 1 -to-S transition. Sirolimus has other cellular effects that probably contribute to its ability to prevent stent restenosis, for instance through the inhibition of the translational regulators p70S6K and 4E-BP1, 210 and, as direct consequence, pathways involved in protein translation. However, the contribution of inhibition of protein translation to the ability of sirolimus to prevent stent restenosis remains unclear. 211 The main action of paclitaxel is to shift the cytoskeleton equilibrium toward assembly, with a consequent reduction in vascular cell proliferation, migration, and signal transduction. 212 At all phases of the cell cycle, bundles of disorganized microtubes are formed preventing progression through M-phase. 213 The sirolimus-eluting stent is composed of a stainless steel stent, the BX Velocity TM stent (Cordis Cypher TM ), coated with a mixture of polyethylenevinylacetate and polybutylmethacrylate containing 140 μg/mm 2 of rapamycin. The sirolimus stent that is now approved by the Food and Drug Administration (FDA) for use in humans is a slow-release platform (≥28-day drug release). Of note, the levels of sirolimus in the whole blood go below the lower limit of quantifi cation (0.4 ng/mL) 72 hours after stent implantation. 214 The First in Man Study (FIM) testing the sirolimuseluting stent was initiated in 1999 and yielded extraordinary results, with an angiographic restenosis rate of 0% maintained at 4 years and no increase of side effects compared with a bare metal stent. 215 This pioneering study provides invaluable long-term information on sirolimus-eluting stents and seems to mitigate concerns about a potential risk of late restenosis or late side effects.
The randomized study with the sirolimus-eluting BX Velocity TM balloon-expandable stent (RAVEL) included 238 patients treated for revascularization of single, de novo lesions in native coronary arteries. 216, 217 The luminal loss was the primary end point and was signifi cantly lower in the sirolimus stent group (+0.01 mm) than in the standard stent group (0.80 mm, p < .001).
The SIRolImUS-coated BX Velocity TM stent in the treatment of patients with de novo coronary artery lesions (SIRIUS) study was a multicenter, randomized, double-blind 
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In-stent restenosis Restenosis FIGURE 71.3. Evolution of invasive treatment of coronary artery disease. More than 25 years ago percutaneous transluminal coronary angioplasty (PTCA) was introduced in clinical practice. Despite the good results obtained, soon it became evident that renarrowing of the treated vessel occurred in a great percentage of cases. Pathophysiologic studies uncovered the causes of restenosis: thrombus formation, elastic recoil, vessel remodeling, and neointimal hyperplasia. By the mid-1980s, scientists and cardiologists started working on mechanical solutions to prevent restenosis. The result was the introduction of the stent, a metal device that, inserted into the artery after PTCA, can prevent elastic recoil and late vascular remodeling. In 1986 the fi rst stent was inserted into a human coronary artery in Toulouse, France, and in 1994 the fi rst Palmaz-Schatz stent was approved for use in the United States. Despite the fact that stents prevent elastic recoil and vessel remodeling, in-stent restenosis still occurs due to neointimal hyperplasia stimulated by the mechanical insult of the struts of the stent to the vessel wall. This led to the development of strategies to inhibit the proliferation of VSMC. Drug-eluting stents are the successful result of a decade of intense preclinical studies; sirolimus-and paclitaxel-eluting stents are now approved for use in humans and the rate of in-stent restenosis dropped above 10%. The development of new dedicated platforms and the identifi cation of drugs effective also in patients at high risk such as diabetics will further decrease this number and possibly eliminate the problem of restenosis. study enrolling patients with coronary lesions from 15 to 30 mm in length. 218 Such a cohort represents more closely the clinic reality of everyday practice compared with the RAVEL patients. The primary end point was target vessel failure, including cardiac death, myocardial infarction, or target vessel revascularization at 9 months from the treatment. In the Cypher TM -treated group 10.5% of the patients reached the primary end point compared with 19.5% in the control group. Furthermore, the binary in-stent restenosis (2.0%) and the in-lesion restenosis (9.1%) were signifi cantly reduced in the sirolimus group. This large-scale trial confi rmed the safety and proved the effi cacy of the sirolimus-eluting stent also in a cohort of patients presenting lesions at higher risk to develop restenosis compared with the RAVEL. More recently, the Canadian Study of the Sirolimus-Eluting Stent in the Treatment of Patients with Long De Novo Lesions in Small Native Coronary Arteries (C-SIRIUS) 219 and the European Sirolimus-Eluting Stents for Treatment of Patients with Long Atherosclerotic Lesions in Small Coronary Arteries (E-SIRIUS) 220 studies confi rmed the anti-restenotic effect of sirolimus-eluting stents in longer lesions in small vessels. Another randomized study reported that the use of sirolimus-eluting stents to treat atherosclerotic lesions in small coronary arteries reduces restenosis and may also reduce major adverse cardiac events. 221 However, diabetic patients seem to be less responsive to sirolimuseluting stents, with higher rate of restenosis developing at 9 months as compared to nondiabetics. 222 Numerous clinical trials have evaluated paclitaxeleluting stents to prevent in-stent restenosis. In a fi rst study, TAXUS I, the patients received either a slow-release low-dose polymer-coated NIRx Conformer TM stent (Boston Scientifi c Corp., Boston, MA) or a bare stent. 223 The restenosis rate was 0% for the drug-eluting stent and 10.3% for the bare stent. The TAXUS II study compared two different polymer confi gurations, both loaded with a low dose of paclitaxel. 224 Both the slow-release (2.3% vs. 17.9%) and the moderate-release polymer (4.6% vs. 20.2%) reduced the incidence of in-stent restenosis. The TAXUS III trial reported the feasibility of the treatment of in-stent restenosis. 225 TAXUS IV is a large, randomized trial testing the effi cacy of paclitaxel-eluting Express TM stent (Boston Scientifi c Corp.) in patients with de novo lesions. In this trial 1314 patients, who were receiving a stent in a single, de novo coronary artery stenosis were prospectively randomized to the slow-release, polymer-based, paclitaxel-eluting TAXUS stent or an identical-appearing bare-metal Express TM stent (Boston Scientifi c Corp.). 226 After 9 months the rate of angiographic restenosis was significantly reduced from 26.6% to 7.9% with the paclitaxeleluting stent. Statistically signifi cant differences were reached also for the target-lesion revascularization required in 3.0% of the patients who received a paclitaxel-eluting stent, as compared with 11.3% of the group treated with a bare-metal stent. The TAXUS IV demonstrated both the safety and the effi cacy of polymer-based, paclitaxel-eluting stent. Recent post-hoc analysis of TAXUS IV suggested that also among diabetic patients the rate of restenosis is significantly reduced with the use of a paclitaxel-eluted stent compared with a bare stent, but further prospective trials are needed to confi rm these data. 227 Finally, the TAXUS V has enrolled 421 patients to demonstrate a superior or noninfe-rior 9-month target vessel revascularization rate for the TAXUS Express TM paclitaxel-eluting SR stent compared with intracoronary brachytherapy for the treatment of in-stent restenosis. The results of TAXUS V, which are pending, will tell us if such an approach is safe and effective also for the treatment of this diffi cult subset of patients.
Rapamycin-and paclitaxel-eluting stents are the culmination of years of intense research into stent design and pharmacologic studies to abolish neointimal hyperplasia. Instent restenosis is not completely abolished yet, but we are getting very close. Despite the fact that DESs have proved to be extremely effective in the prevention of in-stent restenosis, some important issues still remain to be clarifi ed. The possible increased risk of thrombosis due to incomplete reendothelialization after DES is a potential serious problem that has to be taken carefully into consideration when testing new DESs. For example, the high incidence of stent thrombosis observed in the early paclitaxel studies may be due to high drug concentrations or poor stent design. To avoid such problems, it is important to carry out accurate preclinical studies without rushing into potentially unsafe clinical trials. The need for prolonged regimens of antiplatelet therapy must be also considered. The deployment of DESs does not require particular skills compared with bare stent. However, it is becoming evident from intravascular ultrasonography (IVUS) analysis carried out after DES implantation that an accurate stent placement can be very important to successfully reduce neointimal hyperplasia. Incomplete lesion coverage, the gap between stents, and balloon injury beyond the edges of the stent represent the new face of "geographic miss" in the DES era and have been related to treatment failures. Most of these operatordependent factors occur when treating complicated lesions, often in small and tortuous vessels or at the level of a bifurcation. In the near future the design of dedicated platforms seems to be the major challenge but it won't be an obstacle. We envision in the future DESs that are more fl exible and easier to deliver compared to the one actually available. The identifi cation of drugs effective also in diabetics and in patients resistant to sirolimus or paclitaxel will further decrease the rate of in-stent restenosis and possibly abolish it completely.
Gene Therapy for Enhancement of Endothelial Function and Prevention of Restenosis
Despite the relative ease of delivering genes to endothelium, very few studies have considered endothelial-specifi c transgene expression as a therapeutic modality for cardiovascular disease. This seems paradoxical, considering the prominent role of endothelial dysfunction in cardiovascular disease, and the potential therapeutic value of genetic modulation of endothelial function. [5] [6] [7] Genetic strategies to reduce infl ammation and vascular smooth muscle proliferation may be useful for prevention of postangioplasty restenosis (reviewed elsewhere 228 ).
Endothelial Function
A number of genes could serve as targets for genetic modulation of endothelial function, and therapeutic strategies aimed at reducing oxidative stress should increase NO bioavailability and should help improve endothelial function in cardiovascular disease. In this regard, endothelium-targeted overexpression of antioxidant enzymes such as superoxide dismutase, catalase, or heme oxygenase may provide a strategy to scavenge excess ROS and reduce tissue injury in conditions associated with high oxidative stress such as hypertension, atherosclerosis, and coronary artery disease. 2, 40, 229 The overexpression of vasodilatory and antiproliferative genes such as nitric oxide synthase (NOS) and atrial peptides in the endothelium or the inhibition of endothelium-derived vasoconstrictors and growth factors may be effective in the treatment of hypertension and vascular proliferative disease, whereas the expression of antithrombotic, antiadhesion, or antiinfl ammatory genes may be useful in prevention of plaque rupture, thrombosis, and acute myocardial infarction (MI). The overexpression of NOS in the endothelium by exogenous gene transfer may be particularly suitable for vascular diseases, 230 given the broad vasculoprotective effects of NO.
Neointima Proliferation
Two anti-restenosis gene therapy strategies have been used to inhibit neointimal hyperplasia, using a wide variety of therapeutic targets. Cytostatic strategies involve the inhibition of key proteins regulating cell-cycle progression in order to arrest neointimal cell proliferation. [231] [232] [233] [234] We used this strategy to treat jugular veins in vivo with hemagglutinating virus of Japan (HVJ)-liposome complexes containing antisense oligonucleotide against cell-cycle regulators' proliferating cell nuclear antigen (PCNA) and cdc2 kinase in atherosclerotic New Zealand rabbits prior to carotid artery interpositional grafting 233 (Fig. 71.3) . The gene therapy led to adaptive remodeling of the graft, successfully inducing medial hypertrophy while inhibiting neointimal hyperplasia, to yield conduits that resemble normal arteries 234 (Fig.  71.4) . Subsequent histologic and functional analysis of the treated vein graft showed marked inhibition of graft atherosclerosis, decreased infl ammation, and improved endothelial function 234 (Fig. 71.4 ). More recently, it was reported that the treatment of vein grafts prior to implantation with a decoy deoxyoligonucleotide bearing the consensus binding sequence of E2F-1, a transcriptional factor involved in cell-cycle progression, resulted in prolonged resistance to neointimal hyperplasia and improved the patency of the graft after transplantation. 235 An interesting variant in cytostatic gene therapy involves the targeted expression of the thymidine kinase gene. The gene renders the transduced cells sensitive to antiviral drugs such as ganciclovir, such that treatment with the drugs eradicates the vector targeted cells. This strategy, commonly known as suicide gene therapy, has been used successfully to reduce neointima proliferation in atheromatous iliac arteries from rabbits. 236 Delivery of antiproliferative genes such as those coding for the nitric oxide synthases offer another approach to achieve inhibition of neointima hyperplasia. All three isoforms of nitric oxide have been shown to exert vasculoprotective and antiproliferative effects after gene transfer (reviewed elsewhere 230 ). Endothelial and inducible NOS (iNOS) gene transfer are equally effi cacious in reducing neointimal thick-ening in balloon-injured vessels. [237] [238] [239] [240] Local delivery of antioxidant enzymes such as HO-1 241, 242 and ecSOD 243, 244 by adenovirus has also been shown to inhibit neointima hyperplasia in various animal models of restenosis, possibly due to reduction in infl ammation and oxidative stress during the early phase of vascular injury.
Some trials have also been undertaken to evaluate the effect of cell-cycle inhibition on neointima proliferation and vein graft failure. A phase I prospective, randomized, doubleblind trial of human saphenous vein graft treatment with E2F decoy (Project in Ex-Vivo Vein Graft Engineering Via Transfection, PREVENT-1) was carried out in high-risk patients suffering from peripheral arterial occlusive disease. 245 Using nondistending pressure to deliver the E2F decoy oligonucleotide ex vivo prior to arterial interpositional grafting, we demonstrated that E2F decoy treatment was safe and feasible. Although the results were preliminary, the study provided evidence that cytostatic gene therapy is feasible for clinical application. More recently the PREVENT II has largely confi rmed the fi nding of the PREVENT I trial. The PREVENT II is a randomized double-blinded, placebocontrolled phase II trial designed to evaluate the effect of E2F decoy treatment on coronary artery bypass graft (CABG) failure in 202 patients (half treated with E2F decoy) undergoing bypass surgery for at least two vessels. 246 The interim results confi rmed the feasibility and safety of E2F-1 decoy. Analysis of the secondary end points using quantitative coronary angiography and three-dimensional intravascular ultrasound demonstrated increased patency and adaptive vessel remodeling characterized by reduction in neointimal size and volume in the treated group 1 year after treatment, leading to a 40% reduction in critical stenosis. The results of the PREVENT IV have recently been published. 247 This phase III, multicenter, randomized, double-blind, placebocontrolled trial evaluated the therapeutic effi cacy of ex vivo treatment of autologous vein grafts with E2F decoy (Edifoligide) in 3014 patients from 107 sites undergoing CABG. The primary end point evaluated was vein graft failure, defi ned as death or >75% stenosis in treated vein grafts at 12-to 18month angiographic follow-up. The results showed that Edifoligide was no more effective than placebo in preventing graft failure 12 to 18 months after CABG surgery, 247 and the authors concluded that a longer follow-up period will be necessary to determine whether treatment with the E2F decoy has delayed benefi cial effects to improve the durability of CABG surgery.
Cell-Based Therapy for Vascular Protection and Repair
A developing fi eld in vascular therapeutics is the use of autologous endothelial progenitor cell (EPC) transplantation for repair of damaged vessels and bioengineering of vascular prosthetic grafts and stents. [248] [249] [250] [251] [252] [253] [254] [255] [256] Several groups have reported the identifi cation and isolation of EPCs from adult peripheral blood. 257, 258 These cells are thought to originate from a common hemangioblast precursor in the bone marrow 257, 259 and express endothelial lineage markers such as CD34, Flk-1, VE-cadherin, PECAM-1 (CD31), von Willebrand factor, eNOS, and E-selectin [257] [258] [259] (reviewed elsewhere 260 ) ( Fig. 71.5 ). The cells have high proliferative potential, 257 growth conditions differentiate into mature endothelial cells that can be expanded in culture 257, [261] [262] [263] [264] [265] (reviewed elsewhere 266 ). The relative abundance of circulating EPCs is low in basal conditions. 257, 267 However, the number of circulating cells increases severalfold after exogenous stimulation with cytokines such as VEGF and granulocyte-colony stimulating factor (G-CSF) 265, [268] [269] [270] [271] (reviewed elsewhere 266, 267 ). The mechanisms governing the mobilization, homing, and differentiation of the EPC in vivo have only recently begun to be uncovered. The cells appear to be recruited predominantly to sites of injury such as ischemic myocardium and damaged blood vessels 262, 265, 272 (reviewed elsewhere 267 ), suggesting that signals emanating from the injury site may play a central role in the mobilization, homing, and differentiation processes. Injured tissues release various cytokines, chemokines, adhesion molecules, and extracellular matrix proteins locally, which may act in concert to mediate these processes [273] [274] [275] production of adhesion molecules may provide a microenvironment for implantation and subsequent proliferation and differentiation of the EPC.
We have recently reported that transplantation of autologous EPC into balloon-injured rabbit carotid arteries leads to nearly complete reendothelialization of the denuded vessels as early as 4 days after cell transplantation ( Fig. 71.5 ). 277 In contrast, little evidence of reendothelialization was seen at this time in the untreated vessels ( Fig. 71.6 ). The rapid endothelial recovery of the treated vessels was followed by marked reduction in neointima hyperplasia, whereas a prominent neointima was present in the untreated vessel 4 weeks after the injury (Fig. 71.7) . We showed subsequently that genetic modifi cation with a retroviral vector expressing eNOS potentiates the therapeutic effect of the transplanted cells, pre-sumably by enhancing the vasculoprotective properties of the endothelium (Fig. 71.7) . 252 We proposed that the transplantation of autologous EPC expressing vasculoprotective genes at the time of angioplasty may be useful as a strategy to prevent postintervention complications such as thrombosis and restenosis after revascularization procedures.
More recently, we showed that mobilization of EPC in rats by exogenous administration of G-CSF for several days prior to balloon injury of carotid artery leads to accelerated reendothelialization of the denuded vessels. 278 In contrast, little reendothelialization was seen at this time in injured vessels from untreated animals. The vessels from the treated animals showed a decrease in neointima formation, whereas a prominent neointima was present in the vessels from the untreated animals. We believe that this may represent a approach are major advantages compared to the stent and drug therapies currently in use. However, the long-term outcome of these strategies and their safety for use in patients have not been established.
We 277 and several other groups [248] [249] [250] 254, 255, [282] [283] [284] [285] [286] [287] [288] [289] [290] have also shown the suitability of EPC for the seeding of prosthetic grafts and stents. Seeding of autologous EPC into polytetrafl uoroethylene (ePTFE) segments led to rapid endothelialization of the graft segments after carotid interpositional grafting. 277 Furthermore, the cells remained attached to lumen of the graft for at least 4 weeks after transplantation. Using a similar approach, Kaushal et al. 285 showed that seeding of EPC into decellularized porcine iliac vessels implanted as coronary interposition grafts formed a functional endothelial layer and improved vasodilatory function and patency of the grafts, and Dichek et al. 249 reported that retrovirally transduced sheep endothelial cells overexpressing tissue-type plasminogen activator (t-PA) remained attached to stainless steel intravascular stents after balloon infl ation in vitro. These authors have subsequently demonstrated that the seeded endothelial cells remain attached to the surface of the stent when exposed to pulsatile fl ow in vitro. 286 Others have shown that delivery of proangiogenic cytokine VEGF accelerates endothelialization of stents after deployment in balloon-injured arteries. 267, 287 Recently, Aoki et al. 288 used CD34 antibody coated to metal stents to capture EPC to the stent. Sixteen patients with de novo coronary artery disease were treated with the bioengineered stents novel noninvasive strategy for prevention of restenosis following balloon angioplasty. The emphasis on pretreatment with this strategy of premobilization of EPC represents a paradigm shift in the treatment of restenosis, focusing on prevention rather than rescue. Presumably the increase in abundance of circulating progenitors provides a substrate for rapid endothelial healing and recover following procedural injury, thereby reducing the negative effects of remodeling.
Others have reported evidence that statin therapy 206, 279 and estrogen 280 increases the number of PB-EPC and reduces neointima hyperplasia in animal models of arterial injury. Interestingly, Assmus and colleagues 281 showed that statins reduce senescence and stimulate proliferation of PB-EPC by regulating the activity of crucial cell-cycle genes such as the cyclins and cyclin-dependent kinase inhibitors. These fi ndings suggest that the therapeutic potential of endothelial progenitor cells could potentially be harnessed by noninvasive pharmacologic manipulation and used to accelerate the endogenous repair mechanisms for inhibition of neointimal hyperplasia and prevention of restenosis following revascularization procedures. The simplicity and cost-effectiveness of this in this single-center, prospective nonrandomized trial (HEALING-FIM study: Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First in Man). The authors reported no stent thrombosis, and histologic analysis at 1 month indicated that the percent of luminal stenosis was signifi cantly reduced with the EPC capture stents compared to the stainless steel stents. However, late neointima hyperplasia normally associated with stainless steel stent implantation was not reduced in the EPC capture stents, and the authors attributed this to the instability of the EPC. Nevertheless, this trial established the feasibility and safety of this strategy, and future efforts should focus on improving the stability of the transplanted cells. These fi ndings imply that seeding of stents prior to implantation with genetically modifi ed EPC may be useful for prevention of in-stent restenosis and thrombosis. Mobilization of EPC with cytokines has also been shown to be effective in promoting in vivo endothelialization of prosthetic grafts. Bhattacharya et al. 289 and Shi et al. 290 reported that mobilization of bone marrow by exogenous G-CSF enhances endothelialization and patency of small-caliber prosthetic grafts implanted as carotid interposition grafts in association with an increase in the number of circulating EPCs, suggesting that the mobilized cells are recruited to the site of grafting to participate in endothelialization of the graft.
Summary
The role the endothelium in the maintenance of vascular homeostasis is fi rmly established, and endothelial dysfunction is recognized as the precursor of vascular diseases. Vascular remodeling is a pathophysiologic feature of vascular disease, and neointima hyperplasia is the major cause of restenosis and graft atherosclerosis. Despite the remarkable achievements in the medical and surgical treatment of vascular diseases, hypertension and atherosclerosis remain the major causes of morbidity and premature death, and the still relatively high percentage of restenosis and graft failure following surgical revascularization calls for continued development of novel therapeutic strategies to overcome the defi ciencies of the current approaches.
Given the role of endothelial injury in restenosis, it appears logical that strategies to enhance endothelial recovery should be considered. In this regard, endothelial progenitor cells may provide a substrate for reendothelialization of damaged vessels, and several preclinical studies have attested to the feasibility and potential offered by these cells. Nevertheless, the successful clinical application of cell therapy for vessel repair will have to overcome several technical and biologic hurdles. For example, the scarcity of circulating progenitor cells makes it diffi cult to expand suffi cient the number of cells without incurring the risk of cell senescence, and cells from patients with cardiovascular disease have various degrees of dysfunction, thus limiting their use as an autologous source for vascular repair in these patients. Also, strategies to improve retention and survival of the transplanted cells need to be developed. Genetic engineering may provide an important strategy to enhance the survival, engraftment, and function of these cells and render them effi cient therapeutic vehicles in treatment of vascular disease.
Likewise the success of gene therapies for vascular disease has been limited by the poor effi ciency of the delivery vector systems. The development of vectors with enhanced tropism for the vessel wall and capable of prolonged gene expression may provide a solution to the effi ciency issues associated with vascular gene transfer. As we have learned from the various formulations used in drug-eluting stents for prevention of restenosis, the complexity of the pathologic process involved in restenosis suggests that simultaneous manipulation of multiple targets, such as infl ammation, proliferation, apoptosis, and extracellular matrix, may be necessary for effective and sustained therapeutic benefi t. Many of these novel strategies are currently being developed and evaluated using animal studies, and we should expect to see some of these forthcoming developments moving into clinical trial and into the clinical arena.
